China is in talks with Pfizer Inc to secure a licence that will allow domestic drugmakers to manufacture and distribute a generic version of the U.S. firm's COVID-19 antiviral drug Paxlovid in China, three sources told Reuters.
, a developer of a potential mRNA COVID vaccine, are among those that attended the meeting, the first source said.
For a generic drug to be deemed equivalent to a branded medicine, such tests are required to make sure they work the same way in the body. Following the pandemic period, sales to low-income countries will remain royalty free, lower-middle-income countries and upper-middle-income countries will be subject to a 5% royalty for sales to the public sector and a 10% royalty for sales to the private sector, MPP said at that time.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer in talks with China to market COVID-19 antiviral treatment: ReportChina is reportedly in discussions with Pfizer to secure a license for the U.S. drugmaker's COVID-19 antiviral Paxlovid amid a surge in cases in the mainland.
Read more »
China Covid: WHO warns about under-representing Covid deathsThe health body says it is worried about the risk to life and again urges Beijing for better data.
Read more »
As COVID vaccine and Paxlovid sales decline, analysts want to know what's next for PfizerPfizer is the latest pandemic stock to face questions about its long-term strategy as revenue from its COVID-19 vaccine and antiviral business starts to dry up.
Read more »
China and Philippines agree to 'manage differences' on South China Sea | CNNChinese leader Xi Jinping and his Philippine counterpart Ferdinand Marcos Jr. have agreed to strengthen economic ties and resume talks on oil exploration, as they look to revive their economies amid the pandemic downturn and friction over contested areas of the South China Sea.
Read more »
The Illusion of Time: What's Real?Robert Lawrence Kuhn is the creator, writer, host and executive producer of the PBS television series 'Closer to Truth' — co-created, produced and directed by Peter Getzels — the PBS/public television series and online resource on the cosmos, consciousness and meaning that presents leading scientists, philosophers and creative thinkers discussing fundamental questions. Kuhn has published more than 30 books, including 'The Mystery of Existence: Why Is There Anything at All?' (2013) with philosopher John Leslie, 'Closer to Truth: Challenging Current Belief' (2000), 'Closer to Truth: Science, Meaning and the Future' (2007), 'How China's Leaders Think' (2011) and 'The Man Who Changed China: The Life and Legacy of Jiang Zemin' (2005), the first biography of a living Chinese leader published in China and China’s best-selling book in 2005. Kuhn is a commentator for the BBC, CCTV, CNN and Bloomberg, and a featured columnist in the South China Morning Post and China Daily. He is creator and host of 'Closer to China with R.L. Kuhn' on CCTV News, and of 'China's Challenges,' an award-winning documentary series, also directed by Getzels, broadcast on PBS stations and in China. Kuhn is also an international corporate strategist and investment banker, and he is the founder chairman of The Kuhn Foundation, which produces 'Closer to Truth.' Kuhn has a B.A. in human biology from Johns Hopkins University, a Ph.D. in anatomy/brain research from UCLA and an M.S. (Sloan Fellow) from the Massachusetts Institute of Technology (MIT).
Read more »